Anastrozole vs Enclomiphene
A side-by-side research comparison of Anastrozole and Enclomiphene across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Anastrozole | Enclomiphene |
|---|---|---|
| Full name | Anastrozole (Arimidex) | Enclomiphene Citrate |
| Category | Hormone Replacement | Hormone Replacement |
| Status | FDA-approved prescription | Investigational drug |
| Mechanism | Selectively and reversibly inhibits aromatase (CYP19A1), the enzyme that converts androgens to estrogens. Reduces circulating estradiol levels without affecting other steroid pathways. | Blocks estrogen receptors in the hypothalamus, reducing negative feedback and increasing GnRH pulsatility, which stimulates LH and FSH release for endogenous testosterone production. |
| Molecular weight | 293.37 Da | 598.09 Da |
| Half-life | ~46.8 hours | 10-14 hours |
| Bioavailability | ~80-85% oral | ~50% oral |
| Typical dose | 0.25-0.5 mg | 12.5-25 mg |
| Frequency | 2-3x per week | Daily |
| Route | Oral tablet | Oral capsule |
Anastrozole reported benefits
- Estrogen control
- Reduced water retention
- Prevention of gynecomastia
- Maintained testosterone ratio
- Improved body composition
Enclomiphene reported benefits
- Increased endogenous testosterone
- Preserved fertility
- Improved libido
- Enhanced energy and mood
- No testicular atrophy
Related comparisons
Research and educational reference only. Not medical advice.